Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QS-3g
- Development stage
- Preclinical
- Lead developer
- Anhui Medical University
01
Overview
QS-3g: sourced facts only. name: "RNA-seq and CETSA analyses revealed the targeted inhibition of RAMP1 by QS-3g." [PMID:39427859]; target: "RNA-seq and CETSA analyses revealed the targeted inhibition of RAMP1 by QS-3g." [PMID:39427859]; developer: "Inflammation and Immune Mediated Disease Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, 230032, China; Department of Pharmacy, Obstetrics and Gynecology Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, China." [PMID:39427859]; stage: "To investigate the therapeutic effects of QS-3g on K/BxN STA mice, we used H&E staining, immunofluorescence, immunohistochemistry, micro-CT, and other techniques." [PMID:39427859]
02
Targets
RAMP1 (Receptor activity-modifying protein 1)
Beyond the preview
Go deeper on QS-3g.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QS-3g.